STAT3 and non-small cell lung carcinoma: Once we established that STAT3 hyperactivation might be a key signaling alteration that contributes to primary/de novo nintedanib resistance in NSCLC cells, we explored whether the above-described capacity of silibinin to significantly rescue the sensitivity of NSCLC cells to nintedanib occurred upon silibinin-induced STAT3 inhibition.